Gene · 10800
CYSLTR1: cysteinyl leukotriene receptor 1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. CYSLTR1: cysteinyl leukotriene receptor 1. Genes, record 10800. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/10800
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9Y271 | Cysteinyl leukotriene receptor 1 | 337 | 2 | Ensembl, GeneID, HGNC |
Source UniProt
Patents46
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 42746 | Q9Y271 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 9521 | Q9Y271 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 1206 | Q9Y271 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 1206 | Q9Y271 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 9521 | Q9Y271 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 21624 | Q9Y271 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 21625 | Q9Y271 | Espacenet |
| US 11400116 B2 | 2022-08-02 | 3534 | Q9Y271 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 124595 | Q9Y271 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 124596 | Q9Y271 | Espacenet |
1 to 10 of 46
See all 46 patentsDrugs6
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| CR-3465 | CHEMBL5314389 | Cysteinyl leukotriene receptor 1 antagonist | ANTAGONIST | ChEMBL |
| CR-3465 FREE ACID | CHEMBL5316169 | Cysteinyl leukotriene receptor 1 antagonist | ANTAGONIST | ChEMBL |
| MONTELUKAST | CHEMBL787 | Cysteinyl leukotriene receptor 1 antagonist | ANTAGONIST | ChEMBL |
| MONTELUKAST SODIUM | CHEMBL1200681 | Cysteinyl leukotriene receptor 1 antagonist | ANTAGONIST | ChEMBL |
| PRANLUKAST | CHEMBL21333 | Cysteinyl leukotriene receptor 1 antagonist | ANTAGONIST | ChEMBL |
| ZAFIRLUKAST | CHEMBL603 | Cysteinyl leukotriene receptor 1 antagonist | ANTAGONIST | ChEMBL |
Trials209
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07537868 | MONTELUKAST | PHASE2 | ClinicalTrials.gov | |
| NCT07532993 | MONTELUKAST | PHASE4 | ClinicalTrials.gov | |
| NCT07409714 | MONTELUKAST | EARLY_PHASE1 | ClinicalTrials.gov | |
| NCT07101640 | MONTELUKAST | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT06887673 | MONTELUKAST | EARLY_PHASE1 | ClinicalTrials.gov | |
| NCT06747130 | MONTELUKAST | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT06597682 | MONTELUKAST | ClinicalTrials.gov | ||
| NCT06340984 | MONTELUKAST | PHASE3 | ClinicalTrials.gov | |
| NCT06113640 | MONTELUKAST | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT05959889 | MONTELUKAST | ClinicalTrials.gov |
1 to 10 of 209
See all 209 trialsNIH grants774
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | CYSLTR1 papers | Newest fiscal year |
|---|---|---|---|
| R01AI078908 | Control of Pulmonary Inflammation by Leukotriene E4 | 21 | 2025 |
| U19AI095219 | Pathophysiologic and Therapeutic Mechanisms of Aspirin Exacerbated Respiratory Disease | 19 | 2025 |
| T32AI007306 | Immunologic Basis of Resistance and Hypersensitivity | 12 | 2025 |
| R01AI136041 | Eicosanoid Networks in Aspirin Hypersensitivity | 8 | 2025 |
| U19AI070535 | Airway Inflammation and Airway Remodeling in Severe Asthma | 7 | 2025 |
| R01HL058506 | G Protein-Coupled Receptor Regulation in Airway Myocytes | 6 | 2025 |
| U19AI095227 | Viral and Host Determinants of Infant and Childhood Allergy and Asthma | 4 | 2025 |
| I01BX005073 | Targeting pathogenic innate lymphoid cells in airway disease | 3 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 3 | 2025 |
| R01AI134989 | Type 2 Inflammation and Remodeling Elicited Through an LTE4/OXGR1-dependent pathway | 3 | 2025 |
1 to 10 of 774Source NIH's project files
See all 774 nih grantsPapers1,455
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A CotB1p-mediated one-step immobilization strategy for constructing GPCR affinity chromatography to screen multi-target natural product ligands. | J Pharm Biomed Anal | 2027 | 42800465 | PubTator, text mining | PubMed |
| Author Correction: RNA-binding protein RBM3 intrinsically suppresses lung innate lymphoid cell activation and inflammation partially through CysLT1R. | Nat Commun | 2026 | 42791265 | PubTator, text mining | PubMed |
| Assessment of the binding characteristics of three antagonists toward CysLTR1 by affinity chromatography. | J Chromatogr B Analyt Technol Biomed Life Sci | 2026 | 42705206 | PubTator, text mining | PubMed |
| Neuroinflammation- molecular target based therapeutic approach. | Adv Protein Chem Struct Biol | 2026 | 42448410 | PubTator, text mining | PubMed |
Targeted CysLTR1 Blockade Rescues Myeloid-Mediated Resistance to Immune Checkpoint Inhibition in Solid Malignancies: A Combined Genomic, Emulated Clinical Trial, and Epidemiological Negative-Control Analysis. | Am J Clin Oncol | 2026 | 42418282 | PubTator, text mining | PubMed |
| Redox-sensitive GPCR signaling drives Gq-dependent Ca2+ mobilization and cytokine production in human bronchial epithelial cells. | Am J Physiol Cell Physiol | 2026 | 42314770 | PubTator, text mining | PubMed |
| Integrated machine learning and multi-omics analysis identifies ALOX5 as a potential therapeutic target for tubulointerstitial inflammation in diabetic kidney disease. | Sci Rep | 2026 | 41857149 | PubTator, text mining | PubMed |
| Leukotriene receptor antagonists and eosinophilic granulomatosis with polyangiitis: a disproportionality analysis from FAERS, JADER, CVAR databases integrated with network pharmacology. | PLoS One | 2026 | 41801966 | PubTator, text mining | PubMed |
| Eosinophilic gastroenteritis in a 45-year-old female with epigastric abdominal pain: a rare case report. | Ann Med Surg (Lond) | 2026 | 41789234 | PubTator, text mining | PubMed |
| Regulatory roles of bioactive lipids in vascular homeostasis and remodeling. | Med Rev (2021) | 2026 | 41783891 | PubTator, text mining | PubMed |
1 to 10 of 1,455
See all 1,455 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/10800
GET https://conductscience.org/api/genes/v1/10800/patents?page=2